CINECA IRIS Institutional Research Information System

CALCAGNO, Andrea

CALCAGNO, Andrea  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 60 (tempo di esecuzione: 0.03 secondi).
Titolo Data di pubblicazione Autore(i) File
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 2010 Calcagno A; Milia MG; D'Avolio A; Ndayishimiyae P; Dusabimana P; Bonora S; Cusato J; Simiele M; Rostagno R; Siccardi M; Audagnotto S; Ghisetti V; Di Perri G.
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 2009 Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 2010 Bonora S; Calcagno A; Viganò O; Bigliano P; Rusconi S; Trentini L; Tettoni MC; Orofino G; Salassa B; Bramato C; D'Avolio A; Siccardi M; Colella E; Galli M; Di Perri G
Ceftriaxone cerebrospinal fluid levels in adult patients with meningoencephalitis 2015 L. Baietto; A. Calcagno; A. Romito; P. Bigliano; S. Ecclesia; R. Bertucci; F. Lipani; F.G. De Rosa; G. Di Perri; A. D'Avolio
Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml 2013 Calcagno A; Simiele M; Raviolo S; Alberione C; Audagnotto S; Alcantarini C; Bertucci R; D’Avolio A; Di Perri G; Bonora S.
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 2011 S. Corcione; A. Calcagno; S. Bonora; A. D'Avolio; S. Ferrando; M. Vassallo; S. Nozza; A. Castagna; P. Dellamonica; R. Garraffo; G. Di Perri
Cognitive Rehabilitation Protocol in HIV-AIDS Outpatients with ANI and MND Results and Clinical Applicability 2013 Livelli; A.; Pia L.; Carosella S; Farenga M; Ghisetti V; Calcagno A; Caramello P
Cognitive Rehabilitation Protocol in HIV/AIDS Outpatients with ANI and MND: a pilot study 2013 Livelli A; Orofino G; Pia L; Carosella S; Farenga M; Ghisetti V; Calcagno A; Caramello P
Cognitive Rehabilitation Treatment in HIV/AIDS patients with Asymptomatic Neurocognitive Impairment (ANI) and Mild Neurocognitive Disorders (MND) 2014 Livelli A; Pia L; Orofino G; Carosella S; Farenga M; Penoncelli D; Calcagno A; Caramello P.
Cognitive rehabilitation treatment in HIV/AIDS patients with asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorders (MND) 2014 Livelli A; Orofino G; Pia L; Carosella S; Penoncelli D; Farenga M; Guastavigna M; Calcagno A; Caramello P
Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir 2009 M. Siccardi; A. D’Avolio; S. Bonora; L. Baietto; D. Gatti; A. Calcagno; V. Ghisetti; M. Lanzafame; G. Penco; D. Back; A. Owen; G. Di Perri
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 2013 Antonio D'Avolio; Amedeo De Nicolò; Marco Simiele; Lorena Baietto; Andrea Calcagno; Mauro Sciandra; Laura Trentini; Cristina Tettoni; Letizia Marinaro; Giovanni Di Perri; Stefano Bonora
Determinants of Renal Tubular Dysfunction in HIV-positive Patients of More than 50 Years-old 2014 L. Marinaro; A. Calcagno; M. Simiele; G. Mengozzi; M. Mussa; L. Trentini; M.C. Tettoni; C. Alcantarini; M. Lucchiari; J. Cusato; A. D’Avolio; G. Di Perri; S. Bonora
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 2012 Calcagno A; Gonzalez de Requena D; Simiele M; D’Avolio A; Tettoni MC; Salassa B; Orofino G; Libanore V; Di Perri G; Bonora S
Diagnosis of HIV associated Neurocognitive Disorders in Italian cohort: comparison of Clinical Rating and Deficit Score 2015 Livelli, A; Penoncelli, D; Marcotte, T; Calcagno, A; Vai, D; Bonora, S; Pia, L; Orofino, G
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 2009 Gonzalez de Requena D; Bonora S; Cometto C; Magnani S; D'Avolio A; Milia M; Vigano' O; Di Garbo A; Calcagno A; Siccardi M; Baietto L; Sciandra M; Rusconi S; Di Perri G.
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 2013 L. Marinaro; A. Calcagno; D. Ripamonti; G. Cenderello; V. Pirriatore; L .Trentini; B. Salassa; C. Bramato; G. Orofino; A. D’Avolio; G. Di Perri; S. Rusconi; S. Bonora
Etravirine Plasma Exposure is Associated with virological Response in Experienced HIV-positive Patients 2013 L. Marinaro; A. Calcagno; S. Nozza; C. Aldieri; A. Bigoloni; V. Ghisetti; A. Trentalange; T. Allice; P. Bigliano; A. D’Avolio; G. Di Perri; A. Castagna; S. Bonora
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens 2009 D. Gonzalez de Requena; S. Bonora; A. Calcagno; A. D’Avolio; O. Viganò; L. Baietto; C. Cometto; V. Ghisetti; M. Siccardi; S. Rusconi; G. Di Perri
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 2009 Calcagno A.; Bonora S.; Cometto C.; Fontana S.; Aguilar D.; D'Avolio A.; de Requena D. Gonzalez; Maiello A.; Sinicco A.; Di Perri G